Sonoma Biotherapeutics
Melisa S. Medrano, Ph.D., is an Associate Director of Talent Acquisition at Sonoma Biotherapeutics. She brings experience in scientific recruiting to the role. Dr. Medrano was most recently involved with leading and evolving talent acquisition at NGMBio and was hired across scientific, clinical, and other functions at multiple levels. She was also heavily involved in Diversity, Equity, and Inclusion (DE&I) Initiatives. Prior to NGMBio, Dr. Medrano worked with Gilead Sciences’ talent acquisition team where she sourced roles across a variety of functional areas, including research, development, manufacturing, and supply chain.
Dr. Medrano received her Ph.D. in molecular microbiology at Tufts University, where she studied the pathogenesis of Borrelia burgdorferi in Lyme disease. She received her B.S. in microbiology from New Mexico State University.
This person is not in any teams
This person is not in any offices
Sonoma Biotherapeutics
1 followers
Sonoma Biotherapeutics is developing engineered regulatory T cell (Treg) therapies to treat serious autoimmune and inflammatory diseases driven by an imbalanced immune system. Founded by pioneers in Treg biology and cell therapy, the company is employing proprietary platform technologies and approaches to develop a new generation of targeted Treg cell therapies designed to induce durable immune tolerance to treat and prevent autoimmune and inflammatory diseases. Sonoma Biotherapeutics is based in South San Francisco and Seattle.